Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy - PubMed (original) (raw)

doi: 10.1007/s00330-011-2326-9. Epub 2011 Nov 20.

Elodie Crevisy-Girod, Christine Binquet, Laurence Duvillard, David Masson, Côme Lepage, Samia Hamza, Denis Krausé, Bruno Verges, Anne Minello, Jean-Pierre Cercueil, Patrick Hillon, Jean-Michel Petit

Affiliations

Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy

Boris Guiu et al. Eur Radiol. 2012 Apr.

Abstract

Objectives: The SteatoTest, fatty liver index (FLI) and hepatic steatosis index (HSI) are clinico-biological scores of steatosis validated in general or selected populations. Serum adiponectin (s-adiponectin) and retinol binding protein 4 (s-RBP4) are adipokines that could predict liver steatosis. We investigated whether the Steatotest, FLI, HSI, s-adiponectin and s-RBP4 could be valid predictors of liver steatosis in type-2 diabetic (T2D) patients.

Methods: We enrolled 220 consecutive T2D patients. Reference standard was 3.0 T (1)H-MR spectroscopy (corrected for T1 and T2 decays). Intraclass correlation coefficients (ICCs), Kappa statistic measures of agreement, receiver operating characteristic (ROC) curves were assessed.

Results: Median liver fat content was 91 mg triglyceride/g liver tissue (range: 0-392). ICCs among the Steatotest, FLI, HSI, s-adiponectin, s-RBP4 and spectroscopy were low: 0.384, 0.281, 0.087, -0.297 and 0.048. Agreement between scores and spectroscopy was poor (Kappa range: 0.042-0.281). The areas under the ROC curves were low: 0.674, 0.647, 0.637, 0.616 and 0.540. S-adiponectin and s-RBP4 levels were strongly related to the presence of diabetic nephropathy (P = 0.0037 and P = 0.004; Mann-Whitney).

Conclusion: The SteatoTest, FLI, HSI, s-adiponectin, s-RBP4 are not valid predictors of steatosis in T2D patients. Clino-biological markers cannot replace (1)H-MR spectroscopy for the assessment of liver fat in this population.

Key points: (1) H-MR spectrosopy can reliably estimate the weight fraction of liver steatosis. Type-2 diabetes provides an interesting model for assessing liver steatosis. Clinico-biological markers seem to be invalid predictors for steatosis in type-2 diabetes.

PubMed Disclaimer

References

    1. Eur Radiol. 2009 Jul;19(7):1786-93 - PubMed
    1. MAGMA. 2001 May;12(2-3):141-52 - PubMed
    1. J Clin Endocrinol Metab. 2007 Aug;92(8):3052-9 - PubMed
    1. Gastroenterology. 2009 Sep;137(3):865-72 - PubMed
    1. Diabetes Care. 1999 Mar;22(3):394-8 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources